- Home
- TVGN vs DRRX Comparison
TVGN vs DRRX Comparison
Compare TVGN & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- DRRX
- Stock Information
- Founded
- TVGN 2020
- DRRX 1998
- Country
- TVGN United States
- DRRX United States
- Employees
- TVGN N/A
- DRRX N/A
- Industry
- TVGN Blank Checks
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- DRRX Health Care
- Exchange
- TVGN Nasdaq
- DRRX Nasdaq
- Market Cap
- TVGN 53.6M
- DRRX 44.4M
- IPO Year
- TVGN N/A
- DRRX 2000
- Fundamental
- Price
- TVGN $1.64
- DRRX $0.86
- Analyst Decision
- TVGN
- DRRX Buy
- Analyst Count
- TVGN 0
- DRRX 2
- Target Price
- TVGN N/A
- DRRX $5.00
- AVG Volume (30 Days)
- TVGN 6.3M
- DRRX 83.1K
- Earning Date
- TVGN 11-29-2024
- DRRX 11-13-2024
- Dividend Yield
- TVGN N/A
- DRRX N/A
- EPS Growth
- TVGN N/A
- DRRX N/A
- EPS
- TVGN N/A
- DRRX N/A
- Revenue
- TVGN N/A
- DRRX $8,594,000.00
- Revenue This Year
- TVGN N/A
- DRRX N/A
- Revenue Next Year
- TVGN N/A
- DRRX $3.07
- P/E Ratio
- TVGN N/A
- DRRX N/A
- Revenue Growth
- TVGN N/A
- DRRX N/A
- 52 Week Low
- TVGN $0.26
- DRRX $0.48
- 52 Week High
- TVGN $21.09
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- TVGN 52.11
- DRRX 25.34
- Support Level
- TVGN $1.26
- DRRX $0.82
- Resistance Level
- TVGN $1.76
- DRRX $1.36
- Average True Range (ATR)
- TVGN 0.33
- DRRX 0.13
- MACD
- TVGN -0.07
- DRRX -0.05
- Stochastic Oscillator
- TVGN 46.67
- DRRX 6.45
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .